AzTrials
AzTrials

Thyroid NeoplasmsPhase 2/3NCT07434206

Safety and Efficacy of Dexmedetomidine in Controlling Hemodynamics During Resection of Active Thyroid Secreting Tumors

A Phase 2/3 study testing Dexmedetomidine Injection [Precedex] in people with Thyroid Neoplasms, run by South Egypt Cancer Institute at 1 site in Egypt.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

Experienced anesthesiologists often attempt to anticipate and blunt the hypertensive responses seen in varying degrees at critical moments of surgical stimulation. Additionally, it may take a long time to treat acute intraoperative hypertension using anesthetics, and there may be a subsequent period of hypotension due… Read more about this study

Who is it for?
Ages 20 to 65 years
Conditions the study is for
Thyroid Neoplasms
What is being tested?
Dexmedetomidine Injection [Precedex]
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
80 participants
Where
1 siteEgypt
Study dates
25 Apr 2024to 30 Jun 2026
Phase
Phase 2/3
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 20 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients subjected to thyroid resection surgeries for active thyroid tumors.
  • The enrolled age will be from 20 years to 65 years
  • ASA, I-III and NYHA, I-II.

Who cannot join

  • ASA physical status >III and NYHA >II,
  • body mass index >40 kg/m2,
  • pregnant women,
  • preoperative opioid consumption,
  • Allergy to dexmedetomidine
  • Contraindications as hypotension or cardiovascular compromise
  • Unwilling to participate in the study

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • south Egypt cancer institute

    Asyut, 171516

Other trials in Egypt

About this study

Official title: Safety and Efficacy of Dexmedetomidine in Controlling Hemodynamics During Resection of Active Thyroid Secreting Tumors, A Randomized Multicentric Controlled Clinical Trial

Experienced anesthesiologists often attempt to anticipate and blunt the hypertensive responses seen in varying degrees at critical moments of surgical stimulation. Additionally, it may take a long time to treat acute intraoperative hypertension using anesthetics, and there may be a subsequent period of hypotension due to over-compensation. Most practicing anesthesiologists rely on antihypertensive drugs for the rapid control of elevated arterial blood pressure, when volatile anesthetics and narcotics need to be discontinued for awakening. Relatively high doses of antihypertensive drugs, such as labetalol, nicardipine, or esmolol, are commonly used, regardless of the anesthetic technique.One of the main methods to control arterial blood pressure intraoperatively, was to use a typical antihypertensive regimen on an as-needed basis as well as common methods; adjustments in the concentration of volatile anesthetic.

Read the detailed description

Thyroidectomy is the commonest endocrine surgical procedure being carried out throughout the globe. It is performed for thyroid cancer, solitary thyroid nodules, and autoimmune thyroid disease. The challenging scenarios can be encountered at any stage during thyroidectomy, be it preoperative, intraop or postoperative period .

Anesthesia for thyroid surgery may be complicated by difficult airways due to an enlarged thyroid mass and hemodynamic fluctuations due to thyroid hormone secretion . Cardiac complications are equally challenging as also the presence of various co-morbidities which make the task of anesthesiologist extremely difficult. Thyroid storm can occur during intra-op and post-op period in inadequately prepared surgical patients. The complexity of surgical intervention also adds to these existing challenges. Moreover, there always exists a potential risk of uncontrolled hemorrhage from a vascular injury.

Airway management is important during thyroid surgery. The time from induction of anesthesia and subsequent loss of consciousness to endotracheal intubation is one of the most important stages of anesthesia because of acute and dramatic changes occur in the cardiovascular and respiratory system. Direct laryngoscopy and tracheal intubation potentially increase sympathetic response. Significant increases in plasma adrenaline and noradrenaline levels have been reported within the first five minutes after intubation, which then return to preinduction values.

As a result, tachycardia, hypertension and cardiac arrhythmias may frequently, and hypotension and bradycardia may rarely be encountered. The main reason for the sympathoadrenal response to endotracheal intubation is the stimulation of the supraglottic region. Hemo-dynamic changes begin with laryngoscopy, reach a maximum level within 1-2 minutes, and return to pre-laryngoscopy values after approximately five minutes. While these transient hemodynamic responses do not cause significant problems in healthy individuals, they may have negative consequences in risky cases.

So, a greater focus is required for hemodynamic instability induced by thyroid hormone-secreting tumors or hyperthyroidism. This patient experienced intraoperative hemodynamic instability while manipulating the thyroid mass, which is not typically associated with thyroidectomy except in cases of thyroid storm, which is an acute, severe hypermetabolic state caused by excessive thyroid hormone release or increased adrenal activity. Because of the huge size of the thyroid mass, these abrupt hemodynamic changes during thyroid manipulation can be attributed to carotid baroreceptor baroreflex.

Also, Special attention should be paid to thyroid storms by anesthesiologists. These can occur in patients with uncontrolled hyperthyroidism by a trigger such as surgery. patients show features of tachycardia, hypertension, palpitation, and hyperthermia. In particular, an acute thyroid crisis at the time of anesthetic induction may be mistakenly diagnosed as malignant hyperthermia. In both cases, an increase in blood pressure is the main phenomenon, but in this case, the intraoperative blood pressure suddenly dropped with no response to inotropic (ephedrine) or vasoactive (phenylephrine) agents. There was no evidence to indicate an endocrine surge because the patient was in a euthyroid state, and there was no evidence of a tumor that secreted catecholamines histologically.

There is other several possible causes of intraoperative hemodynamic instability; the first is supposedly baroreflex-mediated hemodynamic instability caused by surgical manipulation during thyroidectomy. In such cases, the mass was too large, and the carotid sinus was depressed and stimulated when the surgeon touched the superior pole of the thyroid gland. The second cause is supposedly acute heart failure or thromboembolism. In thyrotoxicosis, catastrophic events such as dysrhythmia, thromboembolism, and heart failure can occur. However, these events rarely occur in a euthyroid state.

The baroreflex is a short-term mechanism to maintain adequate blood pressure by regulating the sympathetic vasomotor tone. It controls the heart rate, contractility, and peripheral resistance in response to nerve impulses entering the baroreceptors . Baroreceptors are mechano-receptor sensory neurons located in the aortic arch and carotid sinus . They sense a stretch in the arterial wall when the pressure changes . The signals from the baroreceptors will eventually reach the vasomotor center in the brain. The vasomotor center will modulate blood pressure by suppressing sympathetic excitement and increasing the vagal tone on the sinoatrial node of the heart .

The baroreflex is known to adapt to chronic changes in vascular properties by changing its sensitivity and operating set-point. Surgical decompression of the carotid artery led to an acute rebound ipsilateral baroreceptor dysfunction, and haemodynamic instability. Similar phenomena have been observed during experimental evaluation of the baroreflex.

In some cases, the ipsilateral carotid sinus is selectively blocked to prevent transmission of aberrant afferent signals to the CNS. Such nerve blocks do not form part of thyroid surgery. The experience of this case, however, gives us cause to consider whether a unilateral carotid sinus block prior to thyroid mobilization could reduce the incidence and severity of hemodynamic instability in selected cases. This could be performed under direct vision, but should never be undertaken bilaterally.

Experienced anesthesiologists often attempt to anticipate and blunt the hypertensive responses seen in varying degrees at critical moments of surgical stimulation. Additionally, it may take a long time to treat acute intraoperative hypertension using anesthetics, and there may be a subsequent period of hypotension due to over-compensation. Most practicing anesthesiologists rely on antihypertensive drugs for the rapid control of elevated arterial blood pressure, when volatile anesthetics and narcotics need to be discontinued for awakening. Relatively high doses of antihypertensive drugs, such as labetalol, nicardipine, or esmolol, are commonly used, regardless of the anesthetic technique.

In anesthesia practice, to suppress hemodynamic responses to laryngoscopy and tracheal intubation; in addition to pharmacological approach, glossopharyngeal and superior laryngeal nerve blocks can be applied with various drugs. Bolus and infusion applications of dexmedetomidine suppress sympathetic activation in endotracheal intubation and extubation. Dexmedetomidine has found widespread use in many areas of daily anesthesia practice because of its inhibition of sympathetic activity, and reduction in hemodynamic response with its effects on sympathetic nerve endings, induction of sedation, anxiolysis and analgesia with its anesthetic and opioid protective effect without any impact on spontaneous breathing. Tissue perfusion decreases due to decrease in cardiac output and blood pressure secondary to sympatholytic activation of central and peripheral pathways following infusion of its loading dose with resultant prolongation of recovery from neuromuscular block, decrease in the requirement for Musculo relaxant drugs and decrease opioid use, making it attractive for use as an adjunct to general anesthesia.

Dexmedetomidine (Precedex), a potent and highly selective α-2 adrenoceptor agonist, has been described as a unique sedative with analgesic, sympatholytic, and respiratory-preserving properties. It has been approved by the U.S. Food and Drug Administration for short-term sedation (< 24 h) of initially intubated and mechanically ventilated adult patients in the intensive care unit (ICU) and for sedation of non-intubated patients during surgical and other procedures. It's clinical applications have been greatly expanded in recent decades due to many favorable physiological effects. Dexmedetomidine is currently being used off-label intraoperatively in the dose range of 0.2 - 0.7 μg/kg/hr to reduce opioid and anesthetic requirements, which may shorten recovery time.

While it has been suggested that alpha2-agonists decrease the adrenergic response to the trauma of surgery and improve perioperative hemodynamic stability, the most frequently reported adverse reactions to dexmedetomidine use in a Phase III study of 401 patients were hypotension, nausea, and bradycardia. A meta-analysis of several randomized controlled trials of dexmedetomidine in noncardiac surgery found a trend towards improved cardiac outcomes, but the incidence of perioperative hypotension and bradycardia was significantly increased.

One of the main methods to control arterial blood pressure intraoperatively, was to use a typical antihypertensive regimen on an as-needed basis as well as common methods; adjustments in the concentration of volatile anesthetic. The investigator, therefore, designed a study to determine whether the addition of dexmedetomidine would provide a greater perioperative hemodynamic stability in patients undergoing thyroidectomy of active thyroid secreting tumors with less side effects or non.

Aim of the study to Investigate whether adding dexmedetomidine infusion would improve perioperative hemodynamic stability in patients undergoing thyroidectomy for active thyroid secreting tumors with fewer side effects.

After obtaining approval from south Egypt cancer institute's ethics committee, 80 cancer thyroid patients undergoing thyroid resection surgeries will be enrolled in the study. Written informed consent will be taken from each patient.Consented patients were allocated into one of two anesthetic groups: labetalol group or Dexmedetomidine group after being assessed for inclusion and exclusion criteria.

Being tested
Dexmedetomidine Injection [Precedex]
Medical subject headings
Thyroid Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Dexmedetomidine Injection [Precedex]Drug

    Also called precedex infusion group

    The study medications as dexmedetomidine and labetalol was prepared by an anesthesia assistant not involved in the study. A 50 ml syringe was filled with 50 μg dexmedetomidine diluted in normal saline solution in Dexmedetomidine group, while, 1 ml labetalol (50 mg) diluted in N.S solution in a 50 ml syringe for infusion in labetalol group was prepared.

Study groups in NCT07434206
Study groupRoleWhat they receive
labetalol Group (Control group)Active comparatorwhere patients will receive an initial bolus dose of labetalol 20 mg by slow IV injection over a 2-minute period before surgical incision to achieve target hemodynamics. Additional injections of 40 to 80 mg can be given on demand at 10-minute intervals until a desired supine blood pressure is achieved or a total of 300 mg has been used then continuous infusion of diluted labetalol solution will be administered at a rate of 2 mL/min to deliver 2 mg/min to control BP swings intraoperatively.
Receives: Drug: Dexmedetomidine Injection [Precedex]
Dexmedetomidine group (Active Group);Active comparatorwhere patients will receive an iv-bolus dose of 0.5-1 μg/kg of dexmedetomidine over 10 min before surgical incision followed by IV infusion of 0.2 - 0.7 μg/kg/h to control BP intraoperatively.
Receives: Drug: Dexmedetomidine Injection [Precedex]

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Intraoperative hemodynamics

    mean blood pressure values

    Measured: 5 hours intraoperatively

  2. Intraoperative hemodynamics

    heart rate values

    Measured: 5 hours intraoperatively

Secondary outcomes (2)
  1. Intensity of pain

    Intensity of pain at rest measured by 11 point NRS Scale ( 0= no pain, 10= worst imaginable pain)

    Measured: 24 hours postoperatively

  2. Sedation:

    Sedation: assessed by 6 point Ramsay sedation score (RSS).(1=anxious, 6=no response)

    Measured: 24 hours postoperatively

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Feb 2026
  2. Study start25 Apr 2024
  3. Primary completion1 Mar 2026 (estimated)
  4. Study completion30 Jun 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2/3
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Model description
Consented patients were allocated into one of two anesthetic groups: labetalol group or Dexmedetomidine group after being assessed for inclusion and exclusion criteria.
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
80 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07434206
Sponsor's protocol ID
18- 2024-685
Status last verified
Feb 2026
First submitted
7 Jun 2024
Last updated
25 Feb 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 2/3 study testing Dexmedetomidine Injection [Precedex] in people with Thyroid Neoplasms, run by South Egypt Cancer Institute at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 25 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Intraoperative hemodynamics (time frame: 5 hours intraoperatively). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Feb 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in